ATHENA
Research type
Research Study
Full title
ATHENA (UCLH): A study exploring the potential for Anti-psma THErapy in triple-Negative breast cAncer
IRAS ID
322275
Contact name
Karen DeSouza
Contact email
Sponsor organisation
University College London Hospitals NHS Foundation Trust
Duration of Study in the UK
1 years, 3 months, 30 days
Research summary
This research project confronts the challenges posed by triple-negative breast cancer (TNBC), an especially aggressive and treatment-resistant form of breast cancer. The study focuses on a novel molecular imaging and potentially therapeutic target known as FOLH1/PSMA, expressed in up to 60% of TNBC tumours. The primary objective of the project is to characterise the expression of FOLH1/PSMA by PET imaging in patients with secondary TNBC. By leveraging molecular positron emission tomography (PET) imaging, the team aims to use a radiotracer to selectively target TNBC tumour cells while minimising harm to healthy tissues. Given the innovative nature of the study, it is structured as a pilot study, spanning 12 months. The project aims to recruit up to 15 participants with secondary TNBC, assessing the technology's potential to detect FOLH1/PSMA expression using PET-CT imaging. The project team will utilise the pilot data generated from this study to develop apply for funding towards a larger study to offer anti-PSMA targeted therapy to participants with high levels of FOLH1/PSMA expression.
If successful, this project could change practice in the diagnosis and treatment of secondary TNBC. The study addresses an unmet need in breast cancer research. It leverages an existing clinically effective technology with a strong track record with MHRA approval for imaging & therapy in prostate cancer and explores its utility in secondary TNBC.REC name
London - Westminster Research Ethics Committee
REC reference
25/LO/0617
Date of REC Opinion
22 Oct 2025
REC opinion
Further Information Favourable Opinion